Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Integra Lifesciences Holdings (IART) Long-Term Debt Issuances (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Long-Term Debt Issuances for 15 consecutive years, with $49.7 million as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Issuances rose 40.4% to $49.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $720.7 million through Dec 2025, up 48.14% year-over-year, with the annual reading at $720.7 million for FY2025, 48.14% up from the prior year.
  • Long-Term Debt Issuances hit $49.7 million in Q4 2025 for Integra Lifesciences Holdings, down from $603.7 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $603.7 million in Q3 2025 to a low of $600000.0 in Q1 2021.
  • Historically, Long-Term Debt Issuances has averaged $71.9 million across 5 years, with a median of $12.5 million in 2021.
  • Biggest five-year swings in Long-Term Debt Issuances: crashed 99.65% in 2021 and later soared 3532.35% in 2024.
  • Year by year, Long-Term Debt Issuances stood at $12.0 million in 2021, then plummeted by 46.06% to $6.5 million in 2022, then skyrocketed by 180.0% to $18.2 million in 2023, then skyrocketed by 94.51% to $35.4 million in 2024, then skyrocketed by 40.4% to $49.7 million in 2025.
  • Business Quant data shows Long-Term Debt Issuances for IART at $49.7 million in Q4 2025, $603.7 million in Q3 2025, and $12.9 million in Q2 2025.